PACTR202209903019732
Recruiting
Phase 2
Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac Anesthesia: Mansoura Novel Strategy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Mansoura university
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.American Society of Anesthesiologists physical status grade II and ?.
- •2\.Age between 20 and 70 years.
- •3\.either gender.
- •4\.Systolic pulmonary artery pressure greater than 70 mmHg.
Exclusion Criteria
- •1\.Patient refusal.
- •2\.Uncompensated cardiac disease.
- •3\.Severe chronic obstructive pulmonary disease ( COPD) and bronchial asthma.
- •4\.Chest infection.
- •5\.uncontrolled HTN and DM.
- •6\.Preoperative liver and renal disease.
- •7\.Body Mass Index \> 40 Kg/m2\.
- •8\.Hematologic disorders.
- •9\.Neuromuscular disorders.
- •Redo and urgent surgeries.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2012-003921-13-GBniversity College London21
Active, not recruiting
Phase 1
BOsentan for Mild Pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial - BOMPA trialEUCTR2010-020209-33-BEniversity Hospitals Leuven20
Active, not recruiting
Not Applicable
Betablocker Therapy in Pulmonary Arterial HypertensioEUCTR2010-020424-21-NLVU medical center
Completed
Phase 2
Betablocker Therapy in Pulmonary Arterial Hypertensioidiopathische pulmonale hypertensiehigh bloodpressure pulmonary vascular systempulmonary hypertension10019280NL-OMON34177Vrije Universiteit Medisch Centrum30
Active, not recruiting
Not Applicable
SPHERIC-1OE: study of the duration of 12 months for the observation of the use of sildenafil for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease in patients enrolled in the previous study titled SPHERIC-1EUCTR2011-002018-35-ITASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI